These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 25943350)

  • 21. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
    Pierga JY; Bidard FC; Autret A; Petit T; Andre F; Dalenc F; Levy C; Ferrero JM; Romieu G; Bonneterre J; Lerebours F; Bachelot T; Kerbrat P; Campone M; Eymard JC; Mouret-Reynier MA; Gligorov J; Hardy-Bessard AC; Lortholary A; Soulie P; Boher JM; Proudhon C; Charafe-Jaufret E; Lemonnier J; Bertucci F; Viens P
    Ann Oncol; 2017 Jan; 28(1):103-109. PubMed ID: 28177480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
    Bertucci F; Fekih M; Autret A; Petit T; Dalenc F; Levy C; Romieu G; Bonneterre J; Ferrero JM; Kerbrat P; Soulie P; Mouret-Reynier MA; Bachelot T; Lerebours F; Eymard JC; Deblock M; Lortholary A; Hardy-Bessard AC; Barthelemy P; Bonnefoi H; Charafe-Jauffret E; Bidard FC; Viens P; Lemonnier J; Pierga JY
    Lancet Oncol; 2016 May; 17(5):600-11. PubMed ID: 27032301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
    Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
    Yuan P; Xu BH; Wang JY; Ma F; Li Q; Zhang P; Fan Y; Li Q; Wang WM
    Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):465-8. PubMed ID: 22967451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
    von Minckwitz G; Rezai M; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Blohmer JU; Costa SD; Jackisch C; Paepke S; Schneeweiss A; Kümmel S; Denkert C; Mehta K; Loibl S; Untch M
    Ann Oncol; 2014 Jan; 25(1):81-9. PubMed ID: 24273046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.
    Piedbois P; Serin D; Priou F; Laplaige P; Greget S; Angellier E; Teissier E; Berdah JF; Fabbro M; Valenza B; Herait P; Jehl V; Buyse M
    Ann Oncol; 2007 Jan; 18(1):52-57. PubMed ID: 17047001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.
    Makhoul I; Klimberg VS; Korourian S; Henry-Tillman RS; Siegel ER; Westbrook KC; Hutchins LF
    Am J Clin Oncol; 2015 Feb; 38(1):74-9. PubMed ID: 23563210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
    D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F
    Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
    Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
    Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer.
    Brandberg Y; Johansson H; Hellström M; Gnant M; Möbus V; Greil R; Foukakis T; Bergh J;
    Breast Cancer Res Treat; 2020 May; 181(1):87-96. PubMed ID: 32232698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
    Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
    Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
    Iwase M; Ando M; Aogi K; Aruga T; Inoue K; Shimomura A; Tokunaga E; Masuda N; Yamauchi H; Yamashita T; Iwata H
    Breast Cancer Res Treat; 2020 Apr; 180(3):687-694. PubMed ID: 32140811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.
    Toi M; Nakamura S; Kuroi K; Iwata H; Ohno S; Masuda N; Kusama M; Yamazaki K; Hisamatsu K; Sato Y; Kashiwaba M; Kaise H; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Takatsuka Y;
    Breast Cancer Res Treat; 2008 Aug; 110(3):531-9. PubMed ID: 17879158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial.
    Joensuu H; Fraser J; Wildiers H; Huovinen R; Auvinen P; Utriainen M; Villman KK; Halonen P; Granstam-Björneklett H; Tanner M; Sailas L; Turpeenniemi-Hujanen T; Yachnin J; Huttunen T; Neven P; Canney P; Harvey VJ; Kellokumpu-Lehtinen PL; Lindman H
    JAMA Netw Open; 2024 Aug; 7(8):e2429772. PubMed ID: 39186271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.
    Perrone F; Nuzzo F; Di Rella F; Gravina A; Iodice G; Labonia V; Landi G; Pacilio C; Rossi E; De Laurentiis M; D'Aiuto M; Botti G; Forestieri V; Lauria R; De Placido S; Tinessa V; Daniele B; Gori S; Colantuoni G; Barni S; Riccardi F; De Maio E; Montanino A; Morabito A; Daniele G; Di Maio M; Piccirillo MC; Signoriello S; Gallo C; de Matteis A
    Ann Oncol; 2015 Apr; 26(4):675-682. PubMed ID: 25488686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.
    Rais G; Raissouni S; Aitelhaj M; Rais F; Naciri S; Khoyaali S; Abahssain H; Bensouda Y; Khannoussi B; Mrabti H; Errihani H
    BMC Womens Health; 2012 Oct; 12():35. PubMed ID: 23039971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer.
    Yardley DA; Shipley D; Zubkus J; Wright GL; Ward PJ; Mani A; Shastry M; Finney L; DeBusk L; Hainsworth JD
    Clin Breast Cancer; 2019 Feb; 19(1):1-9. PubMed ID: 30245148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.